The latest news from academia, regulators
research labs and other things of interest
Posted: Mar 26, 2011
COIN Coordinates the "Roadmap to Profitability" Nanobio Track at NC Nanotechnology Commercialization Conference
(Nanowerk News) COIN (the Center of Innovation for Nanobiotechnology) invites the community to join the nanobiotechnology and nanomedicine track "Roadmap to Profitability" at the 2011 NC Nanotechnology Commercialization Conference on March 29, 2011 at the Barnhardt Center, UNC Charlotte. NCNCC 2011 is a day and a half event organized by the NC Department of Commerce that typically draws approximately 300 leading nanobiotech and nanotech experts from industry and academia to address key commercialization issues. This nanomedicine track immediately follows COIN's previously-announced nanomedicine workshop "Actionable Strategies for Company Building and Moving to Market."
The conference kicks off at 1 pm with opening remarks before breaking out to several parallel tracks at 1:30 pm. COIN coordinates the "Roadmap to Profitability" afternoon nanobio track of the NCNCC. This year's nanomedicine track focuses on accelerating commercialization of nanomedicines, featuring:
Market overview and investment perspective from two leading analysts and investors
Translational nanomedicine panel that includes views from regulatory and small company representatives
An introduction to nanobio companies with a focus on partnership opportunities
Panel on partnering and business development with industry leaders
Lux Research, the preeminent nanotech consultancy, will review the nanomedicine market landscape, discussing emerging trends, key players, and rising stars, also providing an analysis of how the North Carolina nanomedicine hub fits into the national nanobio ecosystem. Guardant Partners will then provide a nanomedicine investment outlook. The Translational Nanomedicine Panel that follows includes insight into how the EPA's approach to regulating nanomaterials will impact the FDA approach, as well as thoughts from companies that have recently taken nano-enabled devices and pharmaceuticals into clinical development, Pioneer Surgical Orthobiologic and Liquidia.
Next, senior management from several companies either headquartered in or with significant operations in North Carolina will briefly present their company, technology, and their business needs and partnership opportunities. These companies (Elmarco, Centice, and Qualiber) represent a range of stages in company maturity and technology focus. Finally, the afternoon nanobio track will conclude with a business development and open innovation panel. Panelists represent GSK, highlighting a nanobio deal case study, Southeast TechInventures and their work to pull emerging technologies out of universities and into commercial development, and an academic perspective on open innovation and its impact on the nanomedicine space. This panel will be moderated by Campbell Alliance, a leading consultancy in pharma and biotech business development.